Quantum Leap Healthcare Collaborative

I-SPY in the News

Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.

Key Studies Presented at SABCS Demonstrate the Important Role of MammaPrint® for Patient Pre-Selection, Cost-Effectiveness and For Younger Patients

Media Contact:

Jeff Matthews, PhD
University of California San Francisco
jmatthews@ispy2.org